Lomedeucitinib

N/A

Report date: 2026/04/20 20:01:59
NME

Base Information

Drug NameLomedeucitinib
Drug Alias NameTYK2i-CNSBMS-986322
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPsoriasisCentral Nervous System DiseasesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBeeline Medicines CorpBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsPsoriasisCentral Nervous System DiseasesMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A